No Data
No Data
Express News | Precision Biosciences Says Partner TG Therapeutics Gets U.S. FDA Clearance For Investigational New Drug (Ind) Application To Investigate Azercabtagene Zapreleucel (Azer-cel) In Human Clinical Trials For Multiple Sclerosis
Express News | Precision BioSciences Inc - TG Therapeutics Anticipates Commencing a Phase 1 Clinical Trial in 2024.
Express News | Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
JonesTrading Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $30
Precision BioSciences: A Strong Buy on Forthcoming Clinical Milestones and Robust Financials
Express News | Precision BioSciences Had Approximately $123.6M In Cash And Cash Equivalents As Of June 30, With Cash Runway Expected Into The Second Half Of 2026
No Data
Boxman : This is another co. funded by Ven bio !!! Pretty nice